Expert: PALOMA-3 Trial Results, Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV for lung cancer patients.

Related Keywords

Toronto ,Ontario ,Canada ,United States ,American ,Natashab Leighl ,Kennedy Ferruggia ,Princess Margaret Cancer Centre ,Ibm ,American Society Of Clinical Oncology ,Pharmacy Times ,Medical Oncologist ,American Society ,Clinical Oncology ,